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INTRODUCTION
The expression “value-based healthcare” was first in-
troduced in 2006 by Michael E. Porter in a book pub-
lished in collaboration with Elizabeth Olmsted Teisberg 
[1]. It should not be surprising that this proposal came 
from an academic known for his theories on econom-
ics and particularly business strategies and competi-
tion. Rising health care costs are a major global chal-
lenge and health systems should also be evaluated from 
an economic and financial point of view. A number of 
factors contribute to the financial crisis of the health 
systems, including ageing populations and the per-
manently increasing costs of medical technology and 
pharmaceutical products. However, an underlying and 
misunderstood source of healthcare’s escalating costs 
has been the inability of healthcare provider organisa-
tions (such as large hospitals and sanitary structures) to 
properly measure and manage the true costs and value 
of healthcare. 
In this book Porter apply to health systems a con-
cept of business management proposed in his 1985 
best-seller Competitive advantage: creating and sustaining 
superior performance and known as “global value chain” 
(GVCs), that is the full range of activities that are re-
quired to bring a product from its conception, through 
its design, its sourced raw materials and intermediate 
inputs, its marketing, its distribution and its support to 
the final consumer. In the health care marketplace the 
“final consumer” is the patient and according to Porter, 
“value-based care” seems to carry the promise to signifi-
cantly reduce overall costs spent on healthcare, linking 
the prices of diagnostic analyses, drugs and treatments 
to their actual value to patients: «The way to transform 
health care is to realign competition with value for pa-
tients. Value in health care is the health outcome per 
dollar of cost expended» (1, p. 20). 
In a very influential and seminal paper published in 
July 2009 in the NEJM on Value Based Healthcare, 
Porter define value improvement as «better patient 
outcomes relative to the costs of achieving them. The 
single most powerful step to improve health outcomes 
is to just start measuring them at the level of patients 
with a given medical condition – such as breast cancer 
or knee or hip arthritis – or in delivering primary and 
preventative care for patient segments such as healthy 
adults» [2]. In the conclusions of the paper Porter rises 
the «big question» if it is possible to move «beyond a re-
active and piecemeal approach to a true national health 
care strategy centred on value», suggesting that the only 
real solution is «to align everyone in the system around 
a common goal: doing what’s right for patients».
Two questions emerge from this conclusion: 1. What 
is a value «right for patients»? 2. Can this concept of 
value and the relative strategies be applied not only to 
acute and chronic diseases, such as cancer or diabetes, 
but also to rare diseases?
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Abstract
The paper reviews the literature available on value based health care and relates it to 
rare diseases. Starting from the economic definition of value and healthcare evaluation, 
efficacy and efficiency, it includes the equity dimension to define value-based healthcare. 
It embraces also the cultural framework associated to the concepts of health and disease, 
normal and pathological, right or wrong for the patient. The paper highlights that a pre-
vention and recovery view and global evaluation of costs/benefits ratio for rare diseases 
make difficult and limited the applicability of the value-based approach to rare diseases. 
Since epidemiology of rare diseases identified a series of difficulties in applying value-
based public health strategies to rare diseases, the paper underlines the necessity of new 
culture of health and well-being, radically re-examining how to organise the delivery of 
prevention, and healthcare services, and finding alternative ways of empowering and giv-
ing voice to vulnerable and marginalised groups.
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The questions focus on the value “right for patients” 
and if this concept of value and the relative strategies 
be applied to rare diseases.
RESULTS
The last quoted passage of Porter’s paper bring us di-
rectly to the very origins of medical thought and medi-
cal practice and to the theoretical and moral basis of 
medicine and health policies.
Starting from classical times, from the origins of 
the western medical thought, medicine has acquired 
a double status: it is a special form of knowledge and 
a knowledge-based social practice. The Greeks had a 
single expression for designating this double nature, iat-
ricke technè,  translated in Latin with Ars medica and in 
modern language as Medical Art. Medicine is not only 
a scientific discipline and its activities must be evalu-
ated with two different sets of criteria, based respective-
ly on knowledge and in value, looking at what is ‘true’ 
but also at what it is “good”. Therefore, criteria of truth 
must be accompanied by criteria of value. The physi-
cian does not have as sole basis for his or her decision a 
“criterion of truth” (the rules used to judge the accuracy 
of statements and actions) but also a “criterion of value” 
(the moral appropriateness and utility for the patient).
For this reason medicine is an “applied science”, 
which links together knowledge, ethical and practical 
principles [3]. As a science it requires an epistemology, 
a theory of knowledge; as an ‘applied’ practice it requires 
a theory of congruence between actions, possible results 
and their value. In clinical medicine, therefore, each 
medical act must be scientifically grounded but also 
have a value, primarily for the patient. This remains the 
basis of the patient-physician individual relationship. 
In philosophical and linguistic terms, the concept of 
“value” has been applied to two different domains. At 
the general level, there is a difference between moral 
value and the value of objects or processes. Moral val-
ues are those that have to do with the conduct of per-
sons, usually leading to praise or blame and to an ethi-
cal evaluation. The value of objects or processes, on the 
other hand, is linked to that is economically good for 
the society and for the individual person. Ethical values 
and economic values have therefore different domains 
of application. 
In healthcare, however, especially in the case of rare 
diseases, these two aspects are necessarily linked. An 
intervention in these field has always an economic val-
ue, for the individual and for the society, but cannot 
be evaluated without taking into account ethical prin-
ciples, in primis equality and the right to health.
Patient oriented healthcare
According to Michael Porter, the central focus of a 
value-oriented healthcare system must be on increas-
ing value for patients. This corresponds to a profound 
change that has occurred in the last decades in the rela-
tionships between doctors and patients. In fact, one of 
the most important change in the health system of the 
last decades is related to patient and his or her health 
attitudes and behaviours, a cultural change which in-
cludes also the evolution of the role of the physician, 
traditional holder of a power based on exclusive medical 
knowledge. In Italy, from a Censis survey conducted in 
2018, it emerges that the majority of Italians considers 
that the relationships between doctor and patient must 
be based on collaboration in decisions regarding thera-
pies (Figure 1) [4]. 
The spread of health information, through the new 
and traditional media, represented a great driver for the 
transformation of health demand and the physician, who 
is the expert by definition, begins to waver in front of 
an increasingly informed patient, who less and less ac-
cepts the asymmetric dimension of the care relationship. 
In this sense, direct access to health information, above 
all through a powerful information tool like the Inter-
net, has increased disinter-mediated behaviours of the 
patient, for example in the choice of health services, or 
in the exchange of health information among peers [5]. 
The new patient figure (informed, aware, autono-
mous, empowered), becomes the protagonist of indi-
vidual paths of health promotion and protection.
But how to evaluate the value for the patient of the 
health care delivery? 
In the economist’s view the evaluation is limited to 
the economic value, cost effectiveness playing an almost 
exclusive part in current decisions about the funding of 
health practices, institutions, and technologies: «Achiev-
ing high value for patients must become the overarch-
ing goal of health care delivery, with value defined as the 
health outcomes achieved per dollar spent» [6]. In this 
context, the “value” in value-based healthcare is derived 
from measuring health outcomes against the cost of de-
livering the outcomes. However, the risk is to adopt a 
purely payer-centred perspective, where “value” means 
delivering cheap but mediocre services, an advantage for 
payers, not patients. The focus is on minimising the costs 
of each intervention and limiting services rather than on 
maximising value over the entire care cycle. «Lowering 
Costs and Improving Outcomes» becomes an «Health 
Imperative», which aims at identifying «a number of 
factors driving expenditure growth including scientific 
Doctor and patient work together to make decisions
Doctor decides on patient's health and care
Doctor provides information on illness 
and therapies and decisions are taken by patient
58,0% 19,6%
22,4%
Figure 1
The new set-up of the doctor-patient relationship (val. %). 
Source: Censis, 2018. 
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uncertainty, perverse economic and practice incentives, 
system fragmentation, lack of patient involvement, and 
under-investment in population health». [7]
In the present organisation of the healthcare system, 
competition seems to be the key word, but competition 
takes place on discrete services, procedures, tests and 
interventions rather than on the full care cycle: «Nobody 
takes an overall care-cycle perspective, including steps 
to avoid the need for interventions (prevention) and on-
going management of medical conditions to forestall re-
currence (disease management). The current structure 
maintains ways of organising medicine that have long 
been obsolete. The adverse consequences for patient 
value are enormous» [1, p. 5]. Value in health care in 
therefore determined in addressing the patient’s health 
condition over the full cycle of care, from prevention 
and monitoring to treatment and ongoing management. 
This evaluation includes equality of health outcomes, 
equality of resource use, and allocation of resources in 
proportion to the severity of the individual’s ill health. 
Adopting a value-based objective will have profound 
implications for allocation of resources throughout the 
healthcare system.
DISCUSSION
From the individual patient to public health
With the development of public health, which deals 
not with individuals but with populations, another ques-
tion arises:  the traditional synthesis between truth and 
value is still valid for public health and health promotion?
Classically, the mission of public health has been stated 
as “the fulfilment of society’s programs in assuring condi-
tions in which people can be healthy” [8]. Starting from 
the Health Reforms in the 19th century, public health 
agencies have used a large combination of scientific and 
technological tools (basic science, clinical research, epi-
demiology, statistics, behavioural research, health care 
institutions and services, economics, and legislations) to 
understand and control the causes of health threats, ac-
quiring the right tools to systematically prevent, mitigate, 
or suppress these causes in entire populations.
But how to attribute a value to the results of a public 
health programme, the activities of an institution, the 
quality of a preventive or health promotion intervention?
In 1972 Archibald Leman Cochrane exposed in a lec-
ture the results of his analysis of the activities of the Na-
tional Health Service in UK. His lecture (and the short 
book that resulted from it) was entitled Effectiveness and 
Efficiency, and the two words became the guideposts of 
health care in many countries [9]. Effectiveness means 
the adequateness to accomplish a purpose and produc-
ing the intended or expected results. Efficiency means 
performing or functioning in the best possible manner 
with the least waste of time, effort and especially mon-
ey. Treatments and health practices must be measured 
and evaluated by their outcomes and their costs. Co-
chrane’s lecture led directly to the ascent of evidence-
based medicine and indirectly to health reforms based 
on the pursuit of efficient and effective outcomes in 
value-based models.
However, the lecture’s and book’s title left out a third 
essential word, that Cochrane considered of the same 
importance than the first two: equity. Cochrane sug-
gested in fact three criteria for establishing priorities in 
care and prevention: Efficiency, Efficacy, Equity.  If the 
first two “Es” deal with economic value, the third has a 
fundamental ethical aspect and moral value.
Too often, the economic values remain dominant and 
the third dimension, “Equity”, is neglected. Equity is 
a concept which derive directly from the fundamental 
Right to Health included in the Constitution of the 
WHO: «The enjoyment of the highest attainable stan-
dard of health is one of the fundamental rights of ev-
ery human being …» (Preamble). The objective of the 
World Health Organization has been defined as « the 
attainment by all peoples of the highest possible level 
of health» (Art. 1) [10]. Accordingly, any policy and ac-
tivity which impairs an equal enjoyment of the right to 
health and produces discrimination in access to health 
care is ruled off. Equity as a consequence is a funda-
mental value in health care and public health.
A further step in the definition of value in health care 
and public health has the increasing consciousness of the 
importance of the social determinants of health, starting 
with the Commission created by WHO and chaired by 
Sir Michael Marmot. The final report of the Commis-
sion, Closing the gap in one generation, underlines the need 
to take into considerations and the different levels of the 
factors which can modify the health status of an indi-
vidual or a population [11]. As a matter of fact, complex 
interactions exist between age, sex, and constitutional 
factors, with individual lifestyle factors, social and com-
munity networks, and finally general socio-economic, 
cultural and environmental conditions [12]. Socio-eco-
nomic and political context, governance, cultural values, 
living and working conditions, besides behaviours and 
biological factors determines the distribution of health 
and well-being, as well as health inequities.  
In Italy, several surveys carried out in the last years 
by Censis, related to representative samples of about 
1000 Italian adults, show some important changes in 
their health attitudes, opinions and behaviours. First 
of all, the increasing relevance attributed by Italians to 
lifestyles and environmental conditions as determinants 
of health on which it is possible to act [13]. 
A new perspective is taking on a growing weight, with 
a more informed and empowered patient, becoming the 
protagonist of promoting one’s health and new lifestyle 
habits and health-oriented behaviours.
A rich literature on social determinants of health 
emphasises the negative consequences on health expe-
rienced by citizens who are in situations of social dis-
advantage, because of greater exposure to risk factors, 
more consistent vulnerability to illness and disability, 
lower life expectancy. The importance of personal re-
sources is evident also by considering a simple indicator 
as the declared state of health of the ISTAT survey on 
the health condition of the Italians [14]. The percent-
age of people (within groups of the same age) who de-
clare themselves to be healthy increases as the level of 
education (as proxy of social status) increases, as well 
as, on the other hand, the share of those with at least 
two chronic diseases increases when the level of educa-
tion decreases
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Culture matters …
Values are embodied in medical knowledge and 
health practices and the personal experience of health 
and well-being is fundamentally determined by the 
cultural contexts that contribute to make its meaning. 
These frameworks and beliefs inform also the actions of 
policy-makers and health care practitioners as well as 
the people they care for. 
In 2014 a Lancet Commission has suggested a cultur-
ally informed approach to health and well-being, indi-
cating that «the systematic neglect of culture in health 
and health care is the single biggest battier to the ad-
vancement of the highest standard of health worldwide» 
[15]. Culture, as defined by UNESCO, is not a rigid set 
of abstracts ideas and concepts, but a set of «distinctive 
spiritual, material, intellectual and emotional features 
of society of a social group … [which] encompasses, in 
addition to art and literature, life styles, ways of living 
together, value systems, traditions and beliefs» [16]. 
Culture, in its dynamic and diversity, sets the frame-
work for attribute meaning to events and objects, and 
is something all members of families, communities and 
populations share. It frames the sense of reality, deter-
mines the parameters within which decisions are taken 
and actions performed, giving a sense of purpose and 
direction to life. Organisations, institutions, and profes-
sional groups also develop they own culture, which pro-
duces diverse schemas of thought and practices. 
The concepts of health and disease, and the rela-
tive beliefs are part of a cultural framework. Values are 
embodied in medical knowledge and health practices 
and they constitute a set of shared values, which de-
fines what is normal and what is pathological [17], what 
is right or wrong for the patient. Viewing health and 
care in purely clinical terms leaves health systems ill-
equipped to understand the psychological, social and 
cultural determinants of illness and health. Far from a 
purely medical discourse, the culture of care, health and 
well-being is built upon a foundation of shared values 
and beliefs, that must be taken into account.
Health is not the absence of illness, but a search for 
well-being in the diverse conditions of life and accord-
ing to the diverse individual constitutions. Moving from 
the traditional concepts based on the disease to a more 
large concept of health linked with the global well-be-
ing and the realisation of each individual’s life project 
shits the accent of health care and public health policy 
towards people’s subjectively defined experiences and 
perceived needs. In such a way health becomes an ob-
jective that should be pursued and promoted through 
individual and community commitment. 
This is particularly true for rare diseases, where the 
pathological condition is always present, but this does 
not preclude a search for well-being and the accom-
plishment of the individual’s life project. This cultural 
change in health establishes the framework for measur-
ing the value of a specific health care measure or public 
health policy.  
Rare diseases and value-based public health 
The traditional public health approach has been ex-
tremely successful in the developed world, with effec-
tive responses to sudden health crises (e.g., infectious 
outbreaks), persistent health problems (e.g. chronic or 
non-communicable diseases), or in controlling envi-
ronmental risk factors (pollution, accidents, nutrition, 
water, natural disasters). However, this traditional ap-
proach to healthcare seems to have a limited applicabil-
ity to rare diseases, because the diseases are extremely 
diverse and the patients are few and scattered across 
populations. 
The applicability to rare diseases of the value-based 
approach, based primarily on prevention and recovery 
and on global evaluation of costs/benefits ratio seems 
therefore limited. Rare diseases are in fact character-
ised by a large number and broad diversity of disorders. 
This diversity implies a preventive and therapeutical 
approach based on individuality. There are very few 
commons traits between the diverse disorders and the 
category of ‘Rare Diseases’ is an artificial grouping with-
out clear ways to group together diverse diseases. The 
unique link between them seems to be the genetical or 
gestational basis of most of them. As a consequence, 
public health approaches may not seem suitable for 
rare diseases, because the primary measures of suc-
cess relate to the prevention of large numbers of cases, 
measurable health betterments, and the avoidance of 
premature deaths.
Rare diseases constitute a fundamental paradox be-
cause if on one side diversity and individuality seem to 
place rare disease outside the real of public health, on 
the other side the reasons to apply a public health ap-
proach to rare diseases are compelling. Rare diseases 
are a major public health problem and a priority be-
cause persons with rare diseases form a sub-population 
of large dimensions. At the social level, the diagnosis of 
a rare disease can severely affect the lives of patients, 
their families and caregivers, with a substantial eco-
nomic impact for the individuals and the communities 
in general. The consequences of this paradox is that the 
sustainability of health systems for rare diseases share 
additional challenged to those faced by health systems 
that are stressed by the current financial crisis.
Rare diseases are serious chronic diseases, usually be-
ginning in childhood and may be life-threatening. As a 
consequence, they represent for the healthcare system 
challenges fundamentally different from those of more 
common diseases. Rarity significantly complicates the 
tasks, because of the small number of patients, the dif-
ficulties in reaching widely dispersed patients, the lack 
of validated and standardised procedures for care and 
rehabilitation, and limited clinical expertise and expert 
centres. For many rare diseases, basic knowledge on 
the specific cause of the disease, its pathophysiology, 
the natural course of the disease and the relative epide-
miological data is scarce, sometimes totally unavailable. 
This significantly delays or overrides both diagnose, 
care giving and prevention. Case definitions for classifi-
cation are usually lacking and as a consequence screen-
ing strategies and surveillance lack efficiency [18]. The 
knowledge on rare diseases epidemiology has luckily 
increases considerably in the last decades [19] and the 
resulting literature clearly identify a list of difficulties in 
applying value-based public health strategies to them: 
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1. scope and capacity of most registries and databases 
are limited to the pure medical and clinical discourses; 
2. knowledge of most rare diseases is insufficient (“or-
phan diseases”); 3. longitudinal data collections are 
scarce; 4. outcomes of treatment and care are diverse 
and difficult to quantify; 5. diagnosis are difficult and 
often delayed; 6. the development of therapeutics and 
treatments is often fragmented and slow; 7. specialised 
and coordinated medical care are scarse and expensive, 
because of its complexity and multidimensionality; 8. 
standards of care for treatment and rehabilitation are 
not evidence based because health research is necessar-
ily done at small scale.
Furthermore, in the case of rare diseases, if the quan-
titative evaluation of the costs is a relatively easy task, 
much more difficult is to establish the quantity and 
especially the quality of the outcomes. The model of 
“value-based healthcare” is mainly suited for managing 
chronic diseases or conditions like cancer, diabetes, obe-
sity, high blood pressure, chronic obstructive pulmonary 
disease (COPD), or heart diseases. Value-based care 
models focus on helping patients recover from illnesses 
and injuries more quickly and at a minimum cost.
Can this approach still be valid for a large but sparse 
population of individuals affected by disabling, life-
threatening, and largely unpreventable diseases? How 
to evaluated a health outcome in a patient with a rare 
disease? 
A positive answer to these question requires the pro-
posal of a lager view of values, reaffirming that even in 
the case of rare diseases the main aim of stakeholders, 
policy makers and institutions in charge of national 
strategies is to quantify the burden of pathological 
condition and available resources for sustainable and 
resilient health system, taking into account the three 
“Es” proposed by Cochrane, the principles of Efficien-
cy, Efficacy and Equity. But this requires a new culture 
of health and well-being and the need to radically re-
examine how to organise the delivery of prevention, 
wellness, screening, and routine health maintenance 
services, finding alternative ways of empowering and 
giving voice to vulnerable and marginalised groups.
Changing values: vulnerability and resilience
One of the main results of the cultural change in 
health demand is related to a new patient, who is in-
formed, aware, autonomous, and empowered. The pa-
tient’s empowerment is particularly important because 
can translate into a real growth of health awareness and 
culture, with positive results in terms of prevention de-
velopment, increase of ability to recognise symptoms 
and diseases, enhancement of compliance and effective 
management of the health conditions. More specifi-
cally, the patient’s empowerment can represent a value 
especially in rare diseases. As in any serious chronic dis-
eases, the patient’s role becomes strategic, because a 
rare disease is a life-long condition, with a great impact 
on life possibilities and on daily life activities. Patients, 
caregivers and families are protagonists in managing 
the disease and individual and family commitment and 
resources are strategic for coping with its difficulties. 
The outcome of cultural changes on health, in terms 
of patient’s awareness and accountability, is one of the 
most important aspects that can impact not only on 
health behaviours but also on care systems and public 
health objectives.
For this reason, in recognising the patient’s strategic 
role, the necessity and the value of his participation in 
the decisions for the care that concern him and in the 
management of his chronic conditions, we must also 
take into account an equally central aspect, health in-
equalities. Their reduction is an ethical imperative, 
but also a fundamental value for the enhancement of 
the patient’s role in the management of rare diseases. 
Diverse value systems and health views can either pro-
mote or limit the equal distribution of health resources. 
Vulnerable groups face very often barriers to integration 
and participation. 
Vulnerability is at the same time a common every-
day term and a rigorous scientific concept. It underlines 
physical and mental fragility, incapacities to work, to 
socialise and to realise own life project, to construct 
and maintain social networks. Vulnerability quite often 
leads to marginalisation and stigmatisation, to social in-
equalities and health insecurity. Vulnerable populations 
and groups often do not become involved in well-being 
studies, also because they are reluctant to do so, partic-
ularly when they feel alienated or marginalised. This can 
unintentionally reinforce health inequalities and deny 
certain groups a voice in the decision-making processes 
that affect their lives. As for the whole society, often the 
most vulnerable are the most silent. 
If vulnerability has a negative acceptation and a pas-
sive sense, another word and concept implies an active 
attitude in coping with difficulties and bad health con-
ditions: resilience. 
Resilience is usually defined as an individual’s ability 
to successfully adapt to life tasks in the face of social 
disadvantage or highly adverse conditions. Resilience is 
the ability of an individual or a system to ‘bounce back’ 
from a negative experience, to continue to function in 
changing situations or adverse conditions and events, 
re-establishing and eventually developing personal ef-
ficiency and social integration. This implies three dif-
ferent modalities, connected with increasing difficulty 
of the adverse situations: to absorb its consequences, 
to adapt to them, and to trasforme the adversity in the 
possibility of new developments.
Resilience is not a permanent character trait but a 
process of building a structured system with gradual 
discovery of personal abilities and the development 
of proper coping techniques, that allow to effectively 
overcome negative conditions or crises. More generally, 
resilience cans be defined as the ability to maintain nor-
mative behaviours and realise aimed tasks at the various 
stages of life, even when the starting conditions of the 
personal life can be handicapped by a rare disease.
Resilience can be linked to individual persons, but it 
is also a fundamental property of social groups, fami-
lies, associations, professional teams, and also institu-
tions. Resilience must be developed by all the actors of 
the health care for rare diseases 99: patients and their 
families, physicians and caregivers, institutions, asso-
ciations, institutions, industries, international organ-
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isation, NGOs. Evidence suggests that efforts of this 
type have empowered patients with rare diseases and 
their organisations as they seek and obtain wider social 
recognition, more participation in research, and better 
health care [20].
Fostering individual and community resilience in face 
of rare disease conditions is the main aim of a value-
based healthcare. There are several factors that can 
develop and sustain a person’s or a group’s resilience 
and most of them are value-based: the ability to make 
realistic plans and being capable of taking the steps nec-
essary to follow them, a positive self-concept and con-
fidence in one’s strengths and abilities, communication 
and problem-solving skills, and the ability to develop 
and control strong emotions and feelings. Value-based 
public health can help patients to improve their health, 
reduce the incidence and the effect of the disease and 
pathological condition, and live healthier lives [21]. 
Well-being can be reached even in presence of infirmity 
or handicap. An individual with a rare disease should 
enjoy the highest attainable standard of health.
The challenge it to re-evaluate what one takes for 
granted in healthcare and public health and rethink 
the spontaneous assumptions about what is health 
and what will make a person healthier. There are many 
diverse and interrelated cultural practices that can en-
hance resilience and values. In the field of rare disease 
more ambitious objectives are possible within a value-
based paradigm: reduce the impact of disease on pa-
tient, they relatives and caregivers, and on community; 
improve the management of associated health condi-
tions; produce a smooth transition between paediatric 
and adult care; improve the quality of life and life ex-
pectancy; enhance the participation of patients in their 
communities, workplaces, cultural life, and society in 
general; develop of cultural activities and acquiring 
more social recognition.
Genomics, epigenomics and rare diseases
With the complete sequence of the human genome 
we are now in a unique position in the history of medi-
cine to define the genetic basis of human diseases pre-
cisely, with optimal sensitivity and specificity. The pre-
cise molecular characterisation of human disease will 
allow us to understand the basis for disease determin-
ism, susceptibility and environmental influence. The re-
cent development of genome-wide analysis seems to be 
able to offer an explanation for the different phenotypic 
manifestations of the same disease, to obtain disease 
prognosis with greater accuracy and  to establish new 
methods and tools for prevention. The aim becomes 
now to refine and, ideally, personalise disease treatment 
for optimal therapeutic efficacy. Rare diseases look as 
unique, individual diseases and the idea of “individual 
or personalised therapy” seems to be the most promis-
ing approach, especially with the development of new 
personalised biotech products for treating rare diseases.
The new field of epigenetics shown how social con-
texts and determinants can influence genetic makeup. 
Epigenetics, defined as the science that studies “the set 
of modifications to our genetic material that change 
the ways genes are switched on and off” [22], focuses 
not merely on gene expression, but also on how diverse 
factors in our natural and social environments affect 
what genes are expressed and the ways in which they 
are expressed. Environmental factors have a profound 
effect on gene expression, and in the classic “rainbow” 
model of the social determinants of health proposed in 
1993 by Dahlgreen and Whitehead [23], the central 
core with the age, sex and constitutional factors is not 
only a set of causal factors for determining upward the 
individual lifestyle and the general population health 
conditions, but also the result of a downward causation, 
which change the ways in which the constitutional fac-
tors are expressed along the whole life course.
These scientific developments can produce a para-
digmatic change in the concept of health and in public 
health strategies, thanks to the possibility to personalise 
prevention, healthcare and promotion of health. Togeth-
er with the three “Es” proposed by Cochrane (Effec-
tiveness, Efficiency, and Equity) the new paradigm in a 
value-based medicine and health will be based on 4 “Ps”: 
Preventive, Predictive, Participatory, and Personalised. 
CONCLUSIONS
A value-based public health strategy for rare diseases 
should concentrate on a few objective, clearly defined 
by a scientific and ethical analysis, which is in general al-
ready available in the scientific literature, epidemiologi-
cal inquires and policy reports. These objectives include 
the definition of the population impact through epide-
miological research adequate for low-prevalence diseas-
es and the evaluation of the costs associated with these 
diseases, such as medical costs, lifetime productivity 
loss, financial impact on caregivers, and impact on the 
employability of patients. Particularly important are the 
objectives of documenting progression of health status 
and associated quality of life, evaluate health outcomes 
(in the largest sense of the term), evaluate and compare 
health care practices, identifying evidence-based find-
ings on best practices and standards of care, create net-
works to share research, knowledge and values.
In order to attain these objectives new research strat-
egies based on values are needed, integrating the com-
plexities and individuality of lived experiences into an 
expanded evidence base on on health vulnerabilities 
that includes assessments of subjectively defined needs, 
thanks to a narrative and qualitative research and a cul-
ture-centred approach. 
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